HCW Biologics Inc., a clinical-stage biopharmaceutical company based in Miramar, Florida, has announced that it has regained compliance with Nasdaq Capital Market requirements. The company received formal notice from Nasdaq on June 24, 2025, confirming that it meets the minimum stockholders' equity requirement as stipulated by Nasdaq Listing Rule 5550(b)(1). Earlier, on May 13, 2025, HCW Biologics was notified of its compliance with the bid price, public float, and market value requirements. With all listing criteria now satisfied, the company is in full compliance for continued listing on the Nasdaq Capital Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.